Group 1: Company Performance and Market Position - The revenue of traditional Chinese medicine (TCM) increased by 24.49% year-on-year, with the five key TCM products growing by 31.44% year-to-date [3] - Sales revenue of Ganqi Bingmei Tablets rose by 38.84% during the reporting period, and by 54.36% year-to-date [3] - The company has received 32 recommendations from authoritative textbooks, clinical guidelines, and expert consensus for its five key TCM products, indicating strong market and clinical recognition [3] Group 2: Sales Strategy and Market Development - The current sales strategy focuses primarily on public hospitals, which account for approximately 70% of the market, while also developing grassroots hospitals, private hospitals, retail pharmacies, and e-commerce platforms [4] - The company aims to increase its market share in existing markets while exploring new growth opportunities through a multi-channel approach [4][7] Group 3: Research and Development Progress - As of May 2025, the company has integrated its R&D pipeline with Chengdu Aorui Pharmaceutical Co., gaining control over 7 innovative drug projects targeting various cancers and autoimmune diseases [5] - The lead project, ORIC-1940, is currently in clinical phases Ia/Ib, with plans to submit IND applications for two additional projects by the end of this year and the first quarter of next year [5][6] Group 4: Response to Market Challenges - The company acknowledges that centralized procurement has a significant impact on existing products but limited effect on new varieties, and it is exploring diversified development strategies to mitigate price reduction risks [6][7] - The company is actively expanding its product line to include special medical foods and nutrition products, enhancing its market competitiveness [7]

一、行情回顾 市场全天震荡调整，创业板指领跌。创新药概念逆势大涨，睿智医药、海南海药、哈三联等多股涨停。猪肉、鸡肉股拉升，巨星农牧、湘佳股份封板。银行 股继续走强，杭州银行、成都银行创历史新高。下跌方面，高位股集体大跌，王子新材等多股跌停。个股跌多涨少，沪深京三市超4100股飘绿，今日成交 1.16万亿。 根据渤海证券统计，本周多款创新药获批上市，包括恒瑞医药的瑞康曲妥珠单抗、磷罗拉匹坦帕洛诺司琼、苹果酸法米替尼，复星医药的枸橼酸伏维西利、 芦沃美替尼，百济神州的泽尼达妥单抗，泽璟制药的盐酸吉卡昔替尼等，同时美国关税政策边际变化带动 CXO 板块快速反弹。 2025年美国临床肿瘤学会（ASCO）即将于当地时间5月30日至6月3日在美国芝加哥召开。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 = | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华森制药 | 4天4板 | 20.63 | +10.03% | 09:32:48 | 4.42% | 63.72亿 | 公司旗下5个产品完 美拉唑碳酸氢钠 ...

Core Viewpoint - The Chinese medicine sector is experiencing a collective pullback in the A-share market, while the Chinese Medicine ETF (560080) has shown resilience, rising nearly 1% and reaching a new high since January 8 of this year [1] Company News - Huawen Pharmaceutical announced the approval from the Singapore Health Sciences Authority for the registration of its traditional Chinese medicine, Tongxie Ning Granules, for sale in Singapore. This marks the fourth overseas registration for the company, following previous approvals for other products [3] - Tongxie Ning Granules is the first natural plant medicine globally for treating IBS-D, demonstrating significant efficacy and high safety, with the ability to prevent recurrence [3] Industry Insights - Huafu Securities indicates that the pressure from high base numbers in the Chinese medicine sector has cleared in the first quarter, with expectations for gradual improvement in performance from Q2 to Q3 of 2025 due to low valuation and low allocation [4] - The firm identifies three major catalysts for the Chinese medicine industry: 1. Accelerated approval and market entry of innovative Chinese medicines, with 9 new drugs approved in 2023 and an expected increase to 16 in 2024 [6] 2. Anticipated adjustments to the essential drug catalog, which will favor innovative Chinese medicines, with a significant increase in the number of traditional Chinese medicine varieties included [6] 3. A decline in the prices of Chinese medicinal materials and expectations for product price increases, which could enhance performance for companies using these materials [7] Key Indicators - The core indicators for the Chinese medicine sector include flu data and the price index of medicinal materials. The flu cases have returned to normal levels, and the pressure on revenue growth for most companies is expected to ease from Q2 2025 [8] - The price index of medicinal materials has been declining since mid-July 2024, with common materials like Lianqiao and Dangshen also showing price decreases, which may alleviate gross margin pressures for companies in 2025 [8]

Pharmaceutical Sector - Huason Pharmaceutical has achieved a 10.03% increase over four consecutive trading days, driven by solid beverage products [2] - Rongzhishiyao has seen a 19.98% rise over two days, attributed to its food and beverage innovations [2] - Qianhong Pharmaceutical recorded a 10.03% increase over three days, linked to its innovative drug offerings [2] - Hainan Haiyao debuted with a 10.07% rise, supported by its innovative drug initiatives [2] - NuoSilande and Warner Pharmaceuticals have both shown significant gains of 22.82% and 19.98% respectively, due to their innovative drug developments [3] Digital Currency Sector - Yuyin Co. has increased by 10.07% over three days, driven by developments in digital currency [5] - Hailian Maohui has also seen a 10.04% rise over two days, attributed to digital currency trends [6] - The Hong Kong Legislative Council passed the Stablecoin Bill, which is expected to lead to the official launch of stablecoins by the end of this year [4] Autonomous Vehicles Sector - Debon Logistics has achieved a 9.99% increase over four consecutive days, driven by developments in unmanned logistics vehicles [8] - Zhongli Co. has seen a 10.00% rise over two days, also linked to the unmanned logistics vehicle sector [8] - Xiaoma Zhixing announced a strategic cooperation with Guangzhou Public Transport Group to collaborate on autonomous driving and logistics services [7] Commercial Aerospace Sector - Zhongheng Design debuted with a 9.98% increase, attributed to developments in the commercial aerospace sector [10] - Zhongtian Rocket also saw a 10.00% rise, linked to advancements in commercial aerospace [10] Other Notable Stocks - Palm Co. has achieved a 10.00% increase over ten days, reflecting strong market interest [15] - Debon Co. has recorded a 9.99% rise over four consecutive days, indicating sustained investor confidence [15]

Group 1 - The innovative drug concept has become active again, with companies like Ruizhi Pharmaceutical reaching a 20% limit up, and others like Kexing Pharmaceutical and Shutaishen rising over 15% [1] - Huason Pharmaceutical has achieved a continuous limit up for four trading days, receiving approval from the Health Sciences Authority of Singapore for its traditional Chinese medicine product, Tongxie Ning granules, which is the first natural plant drug for treating IBS-D globally [1][2] - Tongxie Ning granules are derived from a classic formula and are noted for their efficacy in treating IBS through multiple pathways and targets, with high safety and significant effectiveness [1] Group 2 - Huason Pharmaceutical's recent approval marks the fourth product to achieve overseas registration, enhancing the company's international market recognition [2] - Although the product has not yet been commercialized overseas, successful commercialization could positively impact the company's performance, though it faces uncertainties from market policies, exchange rate fluctuations, and competition [2] - Shutaishen has seen a cumulative increase of over 140% in the last nine trading days, with attention on its subsidiary's application for priority review of the injectable STSP-0601, which is currently in the public notice period [2]

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

暗盘资金流向曝光！提前捕捉庄家建仓信号>> 创新药板块短线拉升，海南海药（000566）、哈三联（002900）、华森制药（002907）涨停，睿智医药 （300149）、诺思兰德涨超10%，舒泰神（300204）、海创药业、三元基因、梓橦宫、热景生物等跟 涨。 ...

Group 1 - The core point of the article is the significant stock price increases of several pharmaceutical companies following the approval of 11 innovative drugs by the National Medical Products Administration on May 29 [1] Group 2 - Harbin Pharmaceutical Group (哈三联) reached the daily limit increase in stock price [1] - Companies such as Ruizhi Pharmaceutical (睿智医药), Xinnowei (新诺威), Hainan Haiyao (海南海药), and Huasen Pharmaceutical (华森制药) saw stock price increases of over 5% [1] - Other companies including Fosun Pharma (复星医药), Yipinhong (一品红), Haiwang Biological (海王生物), and Northeast Pharmaceutical (东北制药) also experienced stock price increases [1]

Group 1 - The innovative drug sector in A-shares has shown a strong comeback, with multiple stocks experiencing significant price increases, including Shuyou Shen (20% increase) and Ruizhi Pharmaceutical (20% increase), indicating a bullish market sentiment [1] - The Hong Kong market also saw a rise, with WuXi AppTec increasing by 19.88% and several innovative drug ETFs in Hong Kong showing year-to-date gains exceeding 40%, outperforming similar products [1][2] - Analysts suggest that the domestic market is entering a concentrated listing period for innovative drugs, supported by comprehensive policy backing and improvements in commercial medical insurance, which are expected to enhance the commercialization process beyond market expectations [1][5] Group 2 - There is a noticeable divergence in the performance of various medical ETFs, with some experiencing significant inflows while others face substantial outflows, indicating mixed investor sentiment [2][3] - The top-performing innovative drug ETFs, such as ICBC Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, have seen net inflows of 2.43 billion and 2.31 billion respectively, while the E Fund CSI 300 Healthcare ETF has recorded the highest net outflow of 2.5 billion [3] - The medical sector is expected to show its best performance in three years by mid-2025, driven by policy optimization and AI industry empowerment, with a clear trend of performance and valuation recovery anticipated in the second half of the year [3] Group 3 - The innovative drug sector has rebounded significantly after a period of decline, with innovative drug ETFs showing substantial weekly gains, particularly in the lead-up to the ASCO annual meeting, which has heightened industry interest [4] - The upcoming ASCO meeting is expected to showcase numerous original research results from Chinese pharmaceutical companies, indicating a shift towards international innovation in drug development [4][5] - Recent approvals of six domestic innovative drugs in May across critical treatment areas such as diabetes and tumors have injected strong momentum into the pharmaceutical industry [5]

证券代码：002907 证券简称：华森制药 公告编号：2025-049 本次公司重点产品痛泻宁颗粒获得新加坡注册批文，是公司继甘桔冰梅片、 六味安神胶囊、都梁软胶囊后第四个成功实现海外注册的产品。此举标志着公司 产品在国际市场的认可度再次提升，这不仅增强了公司在全球医药行业的竞争力， 也为公司带来了更广阔的发展空间和市场机遇，进而推动公司整体国际化战略的 深入实施。此外，痛泻宁颗粒的成功注册，也将促进公司在研发和创新方面持续 投入，公司将不断提升产品质量和技术水平，为全球患者提供更多优质、有效的 医药产品。 | 产 | 品 | 名 | 称 ：TONGXIENING KELI （痛泻宁颗粒） | | --- | --- | --- | --- | | 产 | 品 | 类 | 别 ：中成药 | | 品 | 牌 | 名 | 称 ：华森 | | 剂 | | | 型 ：颗粒剂（内服） | | 生 | 产 | | 商 ：重庆华森制药股份有限公司 | | 注 | 册 | 编 | 号 ：129808 | 二、药品的其他情况 痛泻宁颗粒源于经典名方（"痛泻要方"），为全球首个治疗 IBS-D 的天然 植物药。该药物具有"疏肝理 ...